Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. [PDF]
Yoshifuji K, Sasaki K.
europepmc +1 more source
Uncommon phenotypes of <i>BCR::ABL1</i>-positive chronic myelogenous leukemia. [PDF]
Jajosky AN, Lichtman MA.
europepmc +1 more source
AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects. [PDF]
Gayatri MB +6 more
europepmc +1 more source
Chronic myelogenous leukemia secondary to colon cancer: A case report. [PDF]
Li XL +6 more
europepmc +1 more source
Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature. [PDF]
Allahyari A +3 more
europepmc +1 more source
An interesting case of coexistence of autosomal dominant hypocalcemia 1 with Bartter syndrome and chronic myelogenous leukemia. [PDF]
Chondrogianni ME +9 more
europepmc +1 more source
Expression profiles of miR-411 and SPRY4 as indicators of disease progression and treatment in chronic myelogenous leukemia. [PDF]
Shabannezhad A +5 more
europepmc +1 more source
New onset diabetes manifesting as diabetic ketoacidosis in a patient with chronic myelogenous leukemia treated with imatinib. [PDF]
Salimova D +4 more
europepmc +1 more source
Impact of national volume-based procurement policy on drugs treating chronic Myelogenous Leukemia. [PDF]
Yang Z +7 more
europepmc +1 more source
Protocol for isolation and analysis of the leukemia stem cells in BCR-ABL-driven chronic myelogenous leukemia mice. [PDF]
Liu C, Lin X, Jin Y, Pan J.
europepmc +1 more source

